OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
OTSU.PSX52

Otsuka Pakistan Ltd

PharmaceuticalsVerified

Otsuka Pakistan Ltd operates with a debt-to-equity ratio of 1.37, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.08, suggesting it has just enough current assets to cover its short-term liabilities. However, the company's free cash flow is negative at -34.84 million PKR, and its operating cash flow is 68.10 million PKR, indicating that while it generates positive cash from operations, capital expenditures are consuming more than that. Profitability metrics show a return on equity (ROE) of -2.07% and a return on assets (ROA) of -0.61%, both of which are negative and significantly below the typical performance of the pharmaceutical industry. These figures suggest that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's revenue is concentrated in the domestic market, with no disclosed international operations. This geographic concentration increases exposure to local economic and regulatory risks. The company's revenue of 566.40 million PKR is derived from a single business segment, which is the pharmaceuticals division. There is no indication of diversification into other therapeutic areas or product lines. Looking at the growth trajectory, the company's recent financial performance shows a net loss of 14.58 million PKR, and there is no disclosed revenue growth or expansion into new markets. The capital expenditure of -111.70 million PKR indicates a significant investment in infrastructure or equipment, which may be a precursor to future growth. However, the negative net income and lack of disclosed revenue growth suggest that the company is not currently expanding its market share or increasing its profitability. The risk assessment highlights a key flag: the company has negative net cash after subtracting total debt, which could indicate liquidity stress. The dilution risk is assessed as low, with no near-term pressure from share issuance or dilutive events. The company's liquidity risk is moderate, and its credit risk is not explicitly stated but inferred from the debt-to-equity ratio and negative net cash position. Recent events include the company's latest financial filing, which discloses the financial snapshot and valuation metrics. There are no recent transcripts or press releases indicating significant operational or strategic changes. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.

30-day price · OTSU.PSX-29.80 (-9.6%)
Low$278.00High$393.10Close$280.20As of17 May, 00:00 UTC
Profile
CompanyOtsuka Pakistan Ltd
TickerOTSU.PSX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Otsuka Pakistan Ltd operates with a debt-to-equity ratio of 1.37, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.08, suggesting it has just enough current assets to cover its short-term liabilities. However, the company's free cash flow is negative at -34.84 million PKR, and its operating cash flow is 68.10 million PKR, indicating that while it generates positive cash from operations, capital expenditures are consuming more than that. Profitability metrics show a return on equity (ROE) of -2.07% and a return on assets (ROA) of -0.61%, both of which are negative and significantly below the typical performance of the pharmaceutical industry. These figures suggest that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's revenue is concentrated in the domestic market, with no disclosed international operations. This geographic concentration increases exposure to local economic and regulatory risks. The company's revenue of 566.40 million PKR is derived from a single business segment, which is the pharmaceuticals division. There is no indication of diversification into other therapeutic areas or product lines. Looking at the growth trajectory, the company's recent financial performance shows a net loss of 14.58 million PKR, and there is no disclosed revenue growth or expansion into new markets. The capital expenditure of -111.70 million PKR indicates a significant investment in infrastructure or equipment, which may be a precursor to future growth. However, the negative net income and lack of disclosed revenue growth suggest that the company is not currently expanding its market share or increasing its profitability. The risk assessment highlights a key flag: the company has negative net cash after subtracting total debt, which could indicate liquidity stress. The dilution risk is assessed as low, with no near-term pressure from share issuance or dilutive events. The company's liquidity risk is moderate, and its credit risk is not explicitly stated but inferred from the debt-to-equity ratio and negative net cash position. Recent events include the company's latest financial filing, which discloses the financial snapshot and valuation metrics. There are no recent transcripts or press releases indicating significant operational or strategic changes. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.
Key takeaways
  • Otsuka Pakistan Ltd is a pharmaceutical company with a debt-to-equity ratio of 1.37 and a current ratio of 1.08, indicating moderate liquidity and leverage.
  • The company's profitability is weak, with a negative return on equity of -2.07% and a negative return on assets of -0.61%.
  • Revenue is concentrated in the domestic market, with no international operations disclosed, increasing exposure to local economic and regulatory risks.
  • The company's recent financial performance shows a net loss of 14.58 million PKR, and there is no disclosed revenue growth or expansion into new markets.
  • The risk assessment highlights a key flag: the company has negative net cash after subtracting total debt, which could indicate liquidity stress.
  • The company's liquidity risk is moderate, and its credit risk is inferred from the debt-to-equity ratio and negative net cash position.
  • --
  • **RATIONALES**:
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue$566.4M
Gross profit$103.1M
Operating income$20.9M
Net income-$14.6M
R&D
SG&A
D&A
SBC
Operating cash flow$68.1M
CapEx-$111.7M
Free cash flow-$34.8M
Total assets$2.37B
Total liabilities$1.67B
Total equity$702.8M
Cash & equivalents
Long-term debt$965.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.55B$488.4M$386.3M$416.8M
FY-3$2.85B$371.3M$231.8M$249.8M
FY-2$3.04B$35.9M-$7.2M-$173.8M
FY-1$3.16B$121.8M-$4.8M-$29.4M
FY0$3.78B$162.9M$27.7M-$149.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.49B$501.0M
FY-3$1.85B$713.0M
FY-2$2.29B$697.5M
FY-1$2.29B$675.7M
FY0$2.55B$695.8M
PeriodOCFCapExFCFSBC
FY-4$638.6M-$66.3M$416.8M
FY-3$22.6M-$63.0M$249.8M
FY-2-$129.1M-$247.3M-$173.8M
FY-1$317.9M-$107.4M-$29.4M
FY0$345.4M-$260.1M-$149.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$566.4M$20.9M-$14.6M-$34.8M
FQ-6$1.02B-$28.4M-$28.2M-$17.0M
FQ-5$810.9M-$103.7M-$119.7M-$110.3M
FQ-4$972.8M$217.6M$166.5M$169.3M
FQ-3$884.8M$30.8M$12.6M-$70.7M
FQ-2$1.11B$18.2M-$31.8M-$137.8M
FQ-1$1.08B$179.9M$120.1M$103.7M
FQ0$1.19B$324.6M$209.6M$180.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.37B$702.8M
FQ-6$2.29B$675.7M
FQ-5$2.29B$556.0M
FQ-4$2.25B$722.5M
FQ-3$2.35B$735.1M
FQ-2$2.55B$695.8M
FQ-1$2.64B$815.9M
FQ0$2.81B$1.03B
PeriodOCFCapExFCFSBC
FQ-7$68.1M-$111.7M-$34.8M
FQ-6$317.9M-$107.4M-$17.0M
FQ-5-$144.4M-$9.7M-$110.3M
FQ-4$85.2M-$24.0M$169.3M
FQ-3$154.9M-$129.7M-$70.7M
FQ-2$345.4M-$260.1M-$137.8M
FQ-1$125.2M-$46.6M$103.7M
FQ0$186.5M-$106.4M$180.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$702.8M
Net cash-$965.9M
Current ratio1.1
Debt/Equity1.4
ROA-0.6%
ROE-2.1%
Cash conversion-4.7%
CapEx/Revenue-19.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricOTSU.PSXActivity
Op margin3.7%2.4% medp25 -91.8% · p75 12.5%above median
Net margin-2.6%1.2% medp25 -98.4% · p75 10.4%below median
Gross margin18.2%45.6% medp25 29.8% · p75 66.7%bottom quartile
CapEx / revenue-19.7%-5.2% medp25 -15.8% · p75 -1.7%bottom quartile
Debt / equity137.0%9.3% medp25 0.1% · p75 43.8%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-02 02:41 UTC#0ad3081f
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 21:37 UTCJob: 42b09e13